ArticleJournal of thoracic disease2014

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.

Michael DeGregorio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.